#eisai — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #eisai, aggregated by home.social.
-
https://www.europesays.com/ch/86909/ Takeda, Innovent-Lilly, Roche—Fierce Pharma Asia #Asia #Astellas #BiotechnologyInnovationOrganization #BoehringerIngelheim #china #Chugai #Eisai #FDA #FiercePharmaAsia #FiercePharmaHomepage #Form483 #GLP1 #InnoventBiologics #KyowaKirin #Lenvima #Leqembi #LicensingDeals #Pharma #Roche #SamsungBioepis #Takeda #WuXiAppTec
-
https://www.europesays.com/at/43717/ Eisai präsentiert neue Langzeitdaten zu Alzheimer-Mittel Leqembi #AlzheimerForschung #AlzheimerMittel #ApoE4 #AT #Austria #Eisai #Gesundheit #Health #Langzeitdaten #Leqembi #Österreich #patienten #Risikogen #Studienergebnisse #Therapien
-
https://www.europesays.com/uk/651465/ China’s new commercial insurance model could broaden access to Alzheimer’s drugs #Alzheimer #China #Eisai #EliLilly #Health #Healthcare #Kisunla #Leqembi #pharma #UK #UnitedKingdom
-
https://www.europesays.com/ie/248004/ China’s new commercial insurance model could broaden access to Alzheimer’s drugs #Alzheimer #China #Éire #Eisai #EliLilly #Health #HealthCare #Healthcare #IE #Ireland #Kisunla #Leqembi #pharma
-
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways. https://www.japantimes.co.jp/news/2025/12/12/world/science-health/alzheimers-trials-shift-approach/?utm_medium=Social&utm_source=mastodon #worldnews #sciencehealth #aging #dementia #alzheimer039s #pharmaceuticals #medicine #eisai #novonordisk
-
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways. https://www.japantimes.co.jp/news/2025/12/12/world/science-health/alzheimers-trials-shift-approach/?utm_medium=Social&utm_source=mastodon #worldnews #sciencehealth #aging #dementia #alzheimer039s #pharmaceuticals #medicine #eisai #novonordisk
-
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways. https://www.japantimes.co.jp/news/2025/12/12/world/science-health/alzheimers-trials-shift-approach/?utm_medium=Social&utm_source=mastodon #worldnews #sciencehealth #aging #dementia #alzheimer039s #pharmaceuticals #medicine #eisai #novonordisk
-
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways. https://www.japantimes.co.jp/news/2025/12/12/world/science-health/alzheimers-trials-shift-approach/?utm_medium=Social&utm_source=mastodon #worldnews #sciencehealth #aging #dementia #alzheimer039s #pharmaceuticals #medicine #eisai #novonordisk
-
A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals #eisai #health
-
A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals #eisai #health
-
A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals #eisai #health
-
A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals #eisai #health
-
Each school began with a teacher who adapted what they learned. That’s why we have so many schools. In #Japan alone:
#Eisai studied #Chan in China, came back & founded #Japanese #RinzaiZen.
#Dōgen also went to China, studied Caodong (#Sōtō) & brought it back, reshaping it for #Japan.
#Shinran studied #Tendai, left it, & founded #JōdoShinshū.
#Nichiren followed the #LotusSūtra above all, creating his own movement. (4/10) -
Each school began with a teacher who adapted what they learned. That’s why we have so many schools. In #Japan alone:
#Eisai studied #Chan in China, came back & founded #Japanese #RinzaiZen.
#Dōgen also went to China, studied Caodong (#Sōtō) & brought it back, reshaping it for #Japan.
#Shinran studied #Tendai, left it, & founded #JōdoShinshū.
#Nichiren followed the #LotusSūtra above all, creating his own movement. (4/10) -
Each school began with a teacher who adapted what they learned. That’s why we have so many schools. In #Japan alone:
#Eisai studied #Chan in China, came back & founded #Japanese #RinzaiZen.
#Dōgen also went to China, studied Caodong (#Sōtō) & brought it back, reshaping it for #Japan.
#Shinran studied #Tendai, left it, & founded #JōdoShinshū.
#Nichiren followed the #LotusSūtra above all, creating his own movement. (4/10) -
https://www.alojapan.com/1332000/tokyo-july-25-2025-jcn-newswire/ TOKYO, July 25, 2025 – (JCN Newswire) #Eisai #environment #esg #news #Tokyo #TokyoNews #東京 #東京都 Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index
-
https://www.alojapan.com/1332000/tokyo-july-25-2025-jcn-newswire/ TOKYO, July 25, 2025 – (JCN Newswire) #Eisai #environment #esg #news #Tokyo #TokyoNews #東京 #東京都 Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index
-
Shares of Asian pharmaceutical companies fell after U.S. President Donald Trump announced a plan to order a cut in U.S. prescription drug costs to bring them in line with other countries. https://www.japantimes.co.jp/business/2025/05/12/markets/asian-pharma-trump-drug-price/?utm_medium=Social&utm_source=mastodon #business #markets #medicine #pharmaceuticals #us #republicans #donaldtrump #trade #tariffs #astellas #onopharmaceutical #sumitomopharma #shionogi #eisai #takeda #astellaspharma #otsukaholdings
-
Shares of Asian pharmaceutical companies fell after U.S. President Donald Trump announced a plan to order a cut in U.S. prescription drug costs to bring them in line with other countries. https://www.japantimes.co.jp/business/2025/05/12/markets/asian-pharma-trump-drug-price/?utm_medium=Social&utm_source=mastodon #business #markets #medicine #pharmaceuticals #us #republicans #donaldtrump #trade #tariffs #astellas #onopharmaceutical #sumitomopharma #shionogi #eisai #takeda #astellaspharma #otsukaholdings
-
Shares of Asian pharmaceutical companies fell after U.S. President Donald Trump announced a plan to order a cut in U.S. prescription drug costs to bring them in line with other countries. https://www.japantimes.co.jp/business/2025/05/12/markets/asian-pharma-trump-drug-price/?utm_medium=Social&utm_source=mastodon #business #markets #medicine #pharmaceuticals #us #republicans #donaldtrump #trade #tariffs #astellas #onopharmaceutical #sumitomopharma #shionogi #eisai #takeda #astellaspharma #otsukaholdings
-
Shares of Asian pharmaceutical companies fell after U.S. President Donald Trump announced a plan to order a cut in U.S. prescription drug costs to bring them in line with other countries. https://www.japantimes.co.jp/business/2025/05/12/markets/asian-pharma-trump-drug-price/?utm_medium=Social&utm_source=mastodon #business #markets #medicine #pharmaceuticals #us #republicans #donaldtrump #trade #tariffs #astellas #onopharmaceutical #sumitomopharma #shionogi #eisai #takeda #astellaspharma #otsukaholdings
-
Ebisu-jinja was established by Myōan Eisai (明菴栄西) in 1202 to act as guardian for Kennin-ji (then being built), and to thank the god Ebisu for saving him from a storm when returning from the mainland.
Eisai is credited with bringing the Rinzai school of Zen and the tradition of tea-drinking to Japan.
-
Ebisu-jinja was established by Myōan Eisai (明菴栄西) in 1202 to act as guardian for Kennin-ji (then being built), and to thank the god Ebisu for saving him from a storm when returning from the mainland.
Eisai is credited with bringing the Rinzai school of Zen and the tradition of tea-drinking to Japan.
-
Ebisu-jinja was established by Myōan Eisai (明菴栄西) in 1202 to act as guardian for Kennin-ji (then being built), and to thank the god Ebisu for saving him from a storm when returning from the mainland.
Eisai is credited with bringing the Rinzai school of Zen and the tradition of tea-drinking to Japan.
-
Ebisu-jinja was established by Myōan Eisai (明菴栄西) in 1202 to act as guardian for Kennin-ji (then being built), and to thank the god Ebisu for saving him from a storm when returning from the mainland.
Eisai is credited with bringing the Rinzai school of Zen and the tradition of tea-drinking to Japan.
-
Ebisu-jinja was established by Myōan Eisai (明菴栄西) in 1202 to act as guardian for Kennin-ji (then being built), and to thank the god Ebisu for saving him from a storm when returning from the mainland.
Eisai is credited with bringing the Rinzai school of Zen and the tradition of tea-drinking to Japan.
-
Japan's health ministry on Tuesday approved the production and sale of a new medicine for ALS, raising hopes among patients. https://www.japantimes.co.jp/news/2024/09/24/japan/science-health/japan-new-als-drug-approve/ #japan #sciencehealth #als #eisai #mecobalamin
-
Japan's health ministry on Tuesday approved the production and sale of a new medicine for ALS, raising hopes among patients. https://www.japantimes.co.jp/news/2024/09/24/japan/science-health/japan-new-als-drug-approve/ #japan #sciencehealth #als #eisai #mecobalamin
-
Japan's health ministry on Tuesday approved the production and sale of a new medicine for ALS, raising hopes among patients. https://www.japantimes.co.jp/news/2024/09/24/japan/science-health/japan-new-als-drug-approve/ #japan #sciencehealth #als #eisai #mecobalamin
-
Japan's health ministry on Tuesday approved the production and sale of a new medicine for ALS, raising hopes among patients. https://www.japantimes.co.jp/news/2024/09/24/japan/science-health/japan-new-als-drug-approve/ #japan #sciencehealth #als #eisai #mecobalamin
-
Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain
-
Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain
-
Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain
-
Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain
-
Britain's medicine regulator said Thursday that it approved a novel Alzheimer's drug developed jointly by Japanese drugmaker Eisai and U.S. partner Biogen. https://www.japantimes.co.jp/news/2024/08/23/japan/britain-eisai-drug/ #japan #eisai #alzheimers #drugs #uk
-
Britain's medicine regulator said Thursday that it approved a novel Alzheimer's drug developed jointly by Japanese drugmaker Eisai and U.S. partner Biogen. https://www.japantimes.co.jp/news/2024/08/23/japan/britain-eisai-drug/ #japan #eisai #alzheimers #drugs #uk
-
Britain's medicine regulator said Thursday that it approved a novel Alzheimer's drug developed jointly by Japanese drugmaker Eisai and U.S. partner Biogen. https://www.japantimes.co.jp/news/2024/08/23/japan/britain-eisai-drug/ #japan #eisai #alzheimers #drugs #uk
-
Britain's medicine regulator said Thursday that it approved a novel Alzheimer's drug developed jointly by Japanese drugmaker Eisai and U.S. partner Biogen. https://www.japantimes.co.jp/news/2024/08/23/japan/britain-eisai-drug/ #japan #eisai #alzheimers #drugs #uk
-
European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
-
European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
-
European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
-
Europe's medicines watchdog has rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits. https://www.japantimes.co.jp/news/2024/07/27/japan/science-health/europe-watchdog-alzheimers-drug/ #japan #sciencehealth #eisai #alzheimer039s #aging #health #dementia #medicine
-
Europe's medicines watchdog has rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits. https://www.japantimes.co.jp/news/2024/07/27/japan/science-health/europe-watchdog-alzheimers-drug/ #japan #sciencehealth #eisai #alzheimer039s #aging #health #dementia #medicine
-
Europe's medicines watchdog has rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits. https://www.japantimes.co.jp/news/2024/07/27/japan/science-health/europe-watchdog-alzheimers-drug/ #japan #sciencehealth #eisai #alzheimer039s #aging #health #dementia #medicine
-
Europe's medicines watchdog has rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits. https://www.japantimes.co.jp/news/2024/07/27/japan/science-health/europe-watchdog-alzheimers-drug/ #japan #sciencehealth #eisai #alzheimer039s #aging #health #dementia #medicine
-
Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—http://bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—http://bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—http://bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—http://bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study—FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date — Boehringer, Lilly face off in MASH at EASL—http://bit.ly/w28kSd #moderna #vaccines #flu #covid19 #alzheimers #fda #eisai #biogen #elililly #mash #easl #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma